IP Library › Granted Patent US 11,590,261
Granted Patent B2
US 11,590,261 · App. 16/551,456 · Granted Feb 28, 2023

Method for the preparation of biological tissue for dry use in an implant

Inventors: Nina Foh (Fuerth, DE); Alexander Rzany (Nuremberg, DE); Wilhelm Erdbruegger (Dortmund, DE)
Assignee: Biotronik AG
A61L27/3687A61L27/367A61L27/3625A61L27/58A61L2400/18A61L2430/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,590,261
App. No.
16/551,456
Granted
Feb 28, 2023
Kind
B2
Abstract

A method of preparing biological tissue for use as a component of an implant, in particular as part of a vascular implant, more particularly as part of a heart valve prosthesis, which can be implanted by a catheter. The biological tissue is decellularized using a detergent, which includes surfactin and deoxycholic acid (DCA).

Claims (25)

1. A method of preparing biological tissue for use as a component of an implant, the method comprising decellularizing biological tissue with a detergent comprising surfactin and deoxycholic acid (DCA).

2. The method according to claim 1 , wherein the method is a method of preparing biological tissue for use as a vascular implant.

3. The method according to claim 1 , wherein the detergent comprises about 0.06% surfactin.

4. The method according to claim 1 , wherein the method is a method of preparing biological tissue for use as a heart valve prosthesis.

5. The method according to claim 1 , wherein the detergent comprises about 0.5% DCA.

6. The method according to claim 5 , wherein the detergent comprises about 0.06% surfactin.

7. The method according to claim 1 , the method further comprising cross-linking the decellularized biological tissue with a cross-linking agent.

8. The method according to claim 7 , wherein the cross-linking agent is an aldehyde-containing solution.

9. The method according to claim 7 , the method further comprising performing a structural stabilization step on the decellularized tissue before or after cross-linking.

10. The method according to claim 9 , wherein the structure stabilization step is performed on the decellularized tissue after cross-linking.

11. The method according to claim 9 , wherein the structure stabilization step comprises exposing the decellularized tissue to at least two different solutions, wherein one solution comprises polyethylene glycol and another solution comprises glycerol.

12. The method according to claim 8 , wherein the cross-linking agent is a glutaraldehyde or a formaldehyde containing solution.

13. The method according to claim 8 , wherein the cross-linking agent is glutaraldehyde.

14. The method according to claim 11 , further comprising drying the tissue in a climate chamber by reducing relative humidity.

15. The method according to claim 11 , further comprising drying the tissue in a climate chamber by reducing relative humidity from 95% to 10% over 12 hours at 37° C.

16. The method according to claim 11 , wherein of the at least two different solutions, a first solution comprises polyethylene glycol having a mean molecular weight between 200 g/mol and 600 g/mol; and a second solution is an aqueous solution of polyethylene glycol having a mean molecular weight between 200 g/mol and 6,000 g/mol and glycerol.

17. The method according to claim 11 , wherein the at least two different solutions comprise three different solutions.

18. The method according to claim 17 , wherein the first solution comprises glycerol, the second solution comprises polyethylene glycol having a mean molecular weight of or about 200 g/mol and the third solution comprises polyethylene glycol having a mean molecular weight of or about 400 g/mol, wherein the tissue is exposed to the first and second solutions before the third solution, and wherein the mean molecular weight of the polyethylene glycol is higher in the third solution than the second.

19. The method according to claim 1 , the method further comprising performing a structural stabilization step on the decellularized tissue.

20. The method according to claim 1 , further comprising exposing the decellularized tissue to at least two different solutions, wherein one solution comprises polyethylene glycol and another solution comprises glycerol.

21. The method according to claim 20 , further comprising drying the tissue in a climate chamber by reducing relative humidity.

22. The method according to claim 20 , further comprising drying the tissue in a climate chamber by reducing relative humidity from 95% to 10% over 12 hours at 37° C.

23. The method according to claim 20 , wherein a first solution comprises polyethylene glycol having a mean molecular weight between 200 g/mol and 400 g/mol.

24. The method according to claim 20 , wherein the at least two different solutions comprise three different solutions.

25. The method according to claim 24 , wherein the polyethylene glycol in the third solution has a mean molecular weight of 300 to 1500 g/mol.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2019
From: FOH, NINA; RZANY, ALEXANDER, DR.; ERDBRUEGGER, WILHELM, DR.
To: BIOTRONIK AG
Reel/Frame 050653/0979 →
Priority Claims (1)
EP 14163120 · Apr 2, 2014 · regional
Continuity (2)
Continuation In Part 14671112 · Mar 27, 2015
Related Publication 20190374680A1 · Dec 12, 2019